Information Library
Brochures - Safety & Risk Management
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
Risk Mitigation Programs
April 16, 2009
Risk mitigation measures can help keep valuable drugs on the market, even when their safety profile includes adverse events that might negatively affect the benefit risk balance. -
Risk Assessment & Strategy
April 16, 2009
Quintiles benefit risk analysis can help you anticipate potential regulatory concerns and highlight the benefit side of your drug’s benefit risk profile. -
Phase IIIb/IV Studies
April 16, 2009
New, more efficient delivery models help meet the increasing demands of Phase IIIB/IV Studies. -
Late Phase and Safety Services
April 10, 2009
Recent and pending regulatory changes have created an atmosphere of watchful waiting throughout the industry. While it may seem premature to initiate post-marketing studies to collect more “intelligent” safety data, Quintiles Late Phase & Safety Services anticipates that the need for expanded studies will soon spread.
Page 1 of 1 (4 items)